Harvard Ludwig Cancer Collaborative

Harvard Ludwig Cancer Collaborative

Introduction to Ludwig Center at Harvard Cancer Research Collaborative Joan Brugge, PhD George Demetri, MD Ludwig Cancer Research International community of distinguished scientists dedicated to preventing and controlling cancer Founded by D.K. Ludwig Born in Michigan, 1897; died in NYC, 1992 Self-made billionaire, shipping entrepreneur Provides scientists worldwide with resources and flexibility to realize the life-changing potential of their work Basic and translational research Encompasses the Ludwig Institute and the Ludwig

Centers more than 600 scientists worldwide Invested $2.5 billion in cancer research to date Opportunity at HMS and HMS-affiliated Institutions With senior leaders across HMS and the Boston academic community, we have discussed extensively how best to build the HMS Ludwig Center within the unique environment of the Harvard community in order to have maximum impact on cancer. Factors we considered: Extraordinary breadth and depth of basic, translational and clinical investigators across Harvard Bring in the most diverse set of perspectives, skills and people to develop new ways of addressing a major problem in cancer Enable a novel approach to resistance in cancer Background

Endowment funds are dedicated to supporting cancer research Endowment invested in Harvard Management Fund generates current-use funds to support research long-term Full endowment now allows the Ludwig Center at Harvard to engage a larger community of HMS investigators Since initiation, research funding has been provided to investigators and projects at BWH, DFCI, MGH, and HMS The evolution of Ludwig-supported research in the US and worldwide offers opportunities to enhance communication and collaboration across HMS and link to Ludwig-affiliated investigators outside Harvard Ludwig Center at Harvard Cancer Research Collaborative Overarching goal: to develop strategies that will

overcome resistance that limits the efficacy of anticancer therapies. While significant advances have been made in the treatment of cancer, intrinsic and acquired resistance remain major challenges to reducing the cancer burden. The Ludwig Center at Harvard seeks new ways to understand and address the basic science and clinical problems of resistance to therapeutic interventions Ludwig Center at Harvard Cancer Research Collaborative Key aspects of this initiative: engagement of a broad spectrum of Harvard faculty from the earliest stages

of the project conception and design cross-fertilization at embryonic stage of project development and continued close engagement of investigators as work proceeds develop new ways of thinking about resistance to unravel the complexities of the resistant states from many different perspectives. Ludwigs unique funding model makes it feasible create the infrastructure, incentives, and cultural changes required to build and sustain effective interdisciplinary collaborations in academia. Challenge: Tumor resistance is mediated by MANY different factors Stochastic variation in gene/protein expression Immune escape and

suppression Microenvironment Phenotypic/ Epigenetic alterations (state of differentiation, quiescence or dormancy) Drug induced Adaptive changes -Matrix - Myofibroblasts - Immune cells

- Hypoxia - Acidity Intrinsic or acquired genetic alterations Physical/chem barriers to drug delivery/efficacy - Biomechanical forces - Drug pumps - Drug metabolism Genetic intratumoral heterogeneity adds significant Complexity

Modified from Burrell et al Nature 2013 Inputs Factors that drive therapy resistance feed into common underlying cellular programs that are targets for intervention Intrinsic or acquired genetic alterations Programs regulated by inputs that control cell survival in response to therapy

Microenvironment factors- cell & ECM Stochastic variants Epigenetic phenotypic variants Anti-proliferative ; 16.67% anti-apoptotic; 16.67% Proteostasis; 16.67% anti-oxidant; 16.67% DNA repair; 16.67% anti-necrotic ; 16.67%

Resistant state SURVIVAL Drug-induced adaptive changes The challenge to HMS investigators Want to bring new perspective and understanding to what defines resistant states for cancer cells Define the programs and pathways which contribute to establishing and maintaining resistant states in cancer(s) Identify and develop new tools for understanding basic and clinical principles of resistant states Develop a resource of clinical material and high-fidelity models along with informative clinical annotation to advance the field

DEVELOP EFFECTIVE STRATEGIES TO IMPROVE CURRENT AND EXISTING THERAPIES Launching the collaborative: Process Discuss the organization and overall scientific theme with leaders across HMS and affiliated centers Prepare statement on the scientific theme / challenge Visit basic and clinical research groups across HMS and affiliates to describe vision, goals, and organization Open submissions of short description of novel ideas and approaches to address the research challenge An experiment in research process Build a community of investigators with diverse

backgrounds, perspectives, and skills who want to work together Dedicated time together (weekly meetings to ensure engagement) Develop strategies by cross-fertilization of ideas and approaches across investigators Support with relevant resources Innovation fund to allow new approaches as teams evolve Include major symposia at HMS to strengthen community

Recently Viewed Presentations